

THE LANCET

Microbe

Supplementary appendix 1

This appendix formed part of the original submission and has been peer reviewed.
We post it as supplied by the authors.

Supplement to: Martínez-Martínez FJ, Chiner-Oms Á, Furió V, et al. Genomic determinants of antibiotic resistance for *Helicobacter pylori* treatment: a retrospective phenotypic and genotypic observational study. *Lancet Microbe* 2026. <https://doi.org/10.1016/j.lanmic.2025.101217>

1 **Supplementary File**

2

3 **Title: Genomic determinants of antibiotic resistance for *Helicobacter pylori* treatment:**
4 **a retrospective, phenotypic and genotypic observational study**

5

6

7 **TABLE OF CONTENTS**

8

9 **Extended methods..... 1**

10 Sample acquisition..... 1

11 Distribution of sample collection and resistance prevalence over time2

12 Minimum Inhibitory Concentration (MIC) test for clarithromycin and levofloxacin
13 resistance.....2

14 Isolation and DNA extraction.....2

15 Whole-Genome sequencing with Pacbio.....2

16 Genome assembly.....3

17 Pubmed search to find mutations described with clarithromycin and levofloxacin
18 resistance.....3

19 Statistical association of mutations and phenotypes using a targeted approach.....3

20 Association between genotype, H. pylori subpopulation, and MIC levels.....4

21 Global, genomic-based prevalence of clarithromycin and levofloxacin resistance.....4

22 Screening of resistance-conferring mutations for other antibiotics in the HpGP dataset...4

23 **Extended results..... 5**

24 Distribution of sample collection and resistance prevalence over time5

25 Association of genotypes and ancestral subpopulations.....5

26 **Supplementary figures.....6**

27 **References..... 12**

28 **HpGP Research Network..... 13**

29

30

31

32

33

34

35 **Extended methods**

36 A full description of sampling, bacterial isolation, DNA extraction, long-read sequencing and
37 assembly can be found in the first article of the *Helicobacter pylori* Genome Project (HpGP)
38 published by Thorell and Muñoz-Ramírez *et al.*¹

39 **Sample acquisition**

40 *HpGP* samples were collected from a variety of sources and contributors were identified in
41 international scientific meetings, direct invitations, and referrals. Spain was oversampled due
42 to its colonial impact in Latin America. Sample collection included gastric tissues and
43 cultures from patients with various gastric conditions collected between 1995 and 2020.
44 Eligibility of the biospecimens was confirmed by the US National Cancer Institute and then
45 sent to Vanderbilt University to be processed. A total of 1,011 *H. pylori* strains were
46 analyzed.
47

48 **Distribution of sample collection and resistance prevalence over time**

49 Our dataset was composed of samples collected in the last 30 years. To perform this
50 analysis, we focused on the phenotyped *HpGP* samples, collected specifically between 1995
51 and 2020. In the case of the samples for which we do not dispose of the exact year of
52 collection but a year interval, we consider the mean year. We grouped the samples by 5
53 years and calculated the resistance prevalence, i.e. the number of samples resistant during
54 that period divided by the total amount of samples from that period.

55 **Minimum Inhibitory Concentration (MIC) test for clarithromycin and levofloxacin** 56 **resistance**

57 Agar or broth dilution methods are considered the reference methods for MIC calculation.
58 However, these have rarely been used with *H. pylori* since this pathogen barely grows in
59 broth.² In this study, Etest method has been chosen since it is a quantitative method with a
60 direct expression of MICs and is adapted to slow-growing bacteria like *H. pylori*. In addition,
61 available literature shows a good correlation between this method and agar dilution method.³
62 A quality control in order to verify the compliance of the media used for antibiograms and
63 Etest strips (bioMérieux) to determine MICs was conducted using the *H. pylori* strain CCUG
64 17874, from the Culture Collection University of Gothenburg (Gothenburg, Sweden).

65 **Isolation and DNA extraction**

66 Gastric tissues were homogenized and plated on selective agar for bacterial growth. *H.*
67 *pylori* colonies were then identified using Gram staining and biochemical assays. For each
68 sample, a pool and one single colony were expanded and frozen. In addition, the single
69 colony was also expanded, and its DNA was extracted using Qiagen kits. The original
70 cultures were processed likewise.

71 **Whole-Genome sequencing with Pacbio**

72 DNA sequencing was performed at the US National Cancer Institute using PacBio RSII,
73 Sequel and Sequel II instruments. The libraries were prepared using the SMRTbell Template
74 Prep Kit as recommended by the manufacturer.

75 **Genome assembly**

76 Data obtained from the different PacBio instruments were standardized and analyzed using
77 SMRTLink's HGAP4/Microbial Assembly and Hifiasm v0.13-r308. Contigs were circularized
78 and validated for accuracy and the chromosomal sequences were compared with a
79 reference *H. pylori* strain to confirm high homology.

80 **Pubmed search to find mutations described with clarithromycin and levofloxacin** 81 **resistance**

82 At the beginning of the study, we used the following Pubmed search query to identify the
83 mutations of interest, if any: ("Helicobacter pylori"[MeSH Terms] OR "Helicobacter pylori"[All
84 Fields]) AND ("drug resistance"[MeSH Terms] OR "resistance"[All Fields]) AND
85 ("clarithromycin"[All Fields] OR "levofloxacin"[All Fields]) AND ("mutation"[All Fields] OR
86 "genetic determinants"[All Fields] OR "genomics"[All Fields]). The search was performed on
87 January 10, 2022, and restricted to all scientific articles published until then. No language or
88 article type restrictions were included

89 **Statistical association of mutations and phenotypes using a targeted approach**

90 The *23S rRNA* and *gyrA* and *gyrB* sequences from the 1,011 *HpGP* genomes were
91 extracted with BLASTN v2.5.0, using the *H. pylori* reference genes (GenBank accessions:
92 U27270.1:372-3339 for *23S rRNA*, CP079087.1:752290-754773 for *gyrA* and
93 CP079087.1:527460-529781 for *gyrB*). For each gene, a multiple sequence alignment using
94 MAFFT v7.407 was performed,² specifying the parameter '-keeplength' to maintain the
95 genomic coordinates of the reference sequence for the variant identification and posterior
96 analysis. Later, snp-sites v2.5.1 were run specifying the parameter -v to obtain a VCF file
97 from our alignment.³ Then, taking only the variants of the 419 phenotyped strains as input,
98 we designed a custom R code that counts, for each variant, the number of wildtype and
99 mutant resistant and susceptible strains in the dataset. With this information, a one-tailed
100 upper Fisher's exact test was performed as we were interested in finding those mutations
101 positively associated with resistance. The resulting p-values were corrected with a
102 Bonferroni test to identify potential variants directly involved in antimicrobial resistance by
103 multiplying the p-values by the number of comparisons, i.e., 366 in the case of *23S rRNA*
104 gene, 1154 in the case of *gyrA* gene and 1235 in the case of *gyrB* gene. R version 4.3.2 with

105 the packages stringr v1.5.1, ggplot2 v3.5.1, and the native package stats v.4.3.2 were used
106 in this part.

107 **Association between genotype, *H. pylori* subpopulation, and MIC levels**

108 A Chi-square test was performed to assess the presence of an association between the
109 assigned *H. pylori* subpopulation according to Thorell and Muñoz-Ramírez *et al.*,¹ and the
110 genotype for each strain, focusing on *23S rRNA* and *gyrA* genes. Similarly, a Mann-Whitney
111 U-test was conducted to investigate whether differences in MIC values are linked to specific
112 mutations in those genes (normality of the distribution was not confirmed using the Shapiro-
113 Wilk test, $\alpha < 0.05$ in all categories). R version 4.3.2 with the ggplot2 v3.5.1 and dplyr
114 v1.1.4 packages and the native package stats v4.3.2 were used in this part.

115 **Global, genomic-based prevalence of clarithromycin and levofloxacin resistance**

116 We used FASTP v0.12.5 to remove low-quality reads,⁴ mapped the reads with BWA v0.7.17-
117 r1188 against the *23S rRNA* (GenBank: U27270.1:372-3339) and *gyrA* (GenBank:
118 CP079087.1:752290-754773) references to keep only those genes for further analysis,⁵
119 prepared a mpileup file with SAMTOOLS v1.19.2 and used it to call the SNPs using VarScan
120 v2.3.7,^{6,7} obtaining the final VCF file. Strains carrying the resistance-associated mutations for
121 the *23S rRNA* and *gyrA* genes were identified.

122 **Screening of resistance-conferring mutations for other antibiotics in the *HpGP*** 123 **dataset**

124 The regimens for which we estimated prevalence of resistance strains contain a diverse set
125 of drugs. All triple clarithromycin-, metronidazole- and rifampicin-based therapies contain a
126 proton pump inhibitor (PPI), clarithromycin, metronidazole and rifampicin accordingly, and
127 amoxicillin. Sequential therapy includes a PPI and amoxicillin in the first phase, and a PPI,
128 clarithromycin and metronidazole in the second phase. Concomitant therapy includes a PPI,
129 amoxicillin, clarithromycin and metronidazole. Hybrid therapy contains a PPI, amoxicillin,
130 clarithromycin and metronidazole. Reverse hybrid therapy contains a PPI, amoxicillin,
131 clarithromycin and metronidazole. Novel concomitant therapy includes a PPI, amoxicillin,
132 clarithromycin and metronidazole. Bismuth-based therapy can contain metronidazole or
133 levofloxacin, plus a PPI, a bismuth salt, amoxicillin or tetracycline. Finally, levofloxacin-
134 containing therapy includes a PPI, levofloxacin and amoxicillin.

135 **Extended results**

136 **Distribution of sample collection and resistance prevalence over time**

137 We explored the trends of prevalence for clarithromycin and levofloxacin according to the
138 collection date of the 419 phenotyped *HpGP* samples collected between 1995 and 2020. As
139 shown in Supplementary Figure 1, samples were mostly collected between 2015 and 2020,
140 with lower sampling in the previous years. Resistance prevalence for clarithromycin and
141 levofloxacin show a slight positive trend, but since the number of samples strongly increases
142 through time, conclusions may be misleading. However, as shown in Appendix 2 p 20, our
143 prevalence estimations overall agree with published data, and as such, we expect this trend
144 to match existing studies.

145


146 **Association of genotypes and ancestral subpopulations**

147 A Chi-square test showed a positive association for the subpopulations hspSWEurope (p-
148 value = 0.0031), hspEAsia (p-value = 0.0057), and hspEurasia (p-value = 0.001), and an
149 inverse association for hspSWEuropeLatinAmerica (p-value = 0.00035) and hspNEurope (p-
150 value = 0.018) (Supplementary Figure 2A) with the *23S rRNA* mutated genotypes, meaning
151 that, respectively, these subpopulations showed a higher and lower frequency of *23S rRNA*
152 mutations than would be expected by chance. Apart from hspEAsia, hspEurasia and
153 hspSWEurope, for which the number of strains is above 40, the number of strains that
154 belong to the other groups was small to perform an individual analysis. Therefore, these
155 populations were pooled in Supplementary Figure 2B to show a broader view of the
156 mutations' frequencies.

157 For the *gyrA* genotypes (Supplementary Figure 2C), mutations on both 87 and 91 codons
158 were found in almost all the population groups, except for hspIndigenousAmerica (only
159 N87K) and hspAfrica1WAfrica (only N87I). However, in these two groups there was only one
160 phenotyped strain for levofloxacin. Smaller populations were pooled in Supplementary
161 Figure 2D to provide a broader view of the frequencies.

162 **Supplementary figures**

163




164 **Supplementary Figure 1.** Trends of clarithromycin and levofloxacin resistance prevalence
165 over a 25 years period according to the 419 phenotyped *HpGP* samples.

166


167

168


169




171



172





175

176 **Supplementary Figure 2. Proportion of the different 23S rRNA (A and B) and gyrA (C**
 177 **and D) mutations by *H. pylori* population group in the HpGP dataset (n= 1,011).**


178 The number at the top of each bar indicates the number of strains with the mutation in the
 179 population group. The total number of strains in the dataset that belong to each of
 180 these groups is: HpAfrica2 4 (0.39%), HpAsia2 34(3.36%), hpNEAfrica 17 (1.68%),
 181 hpNorthAsia 2 (0.20%), hpSahul 1 (0.10%), hspAfrica1MiscAmerica 19 (1.88%),
 182 hspAfrica1NAmerica 58 (5.74%), hspAfrica1SAfrica 38 (3.76%), hspAfrica1WAfrica 8
 183 (0.79%), hspEAsia 166 (16.42%), hspEurasia 200 (19.78%), hspIndigenousAmerica
 184 21 (2.08%), hspNEurope 102 (10.09%), hspSWEurope 172 (17.01%),
 185 hspSWEuropeChile 43 (4.25%), hspSWEuropeLatinAmerica 114 (11.28%), hspUral
 186 12 (1.19%). Plots B and D show the most common populations along with the pooled
 187 values for the rest of populations.

188


189

190

191



193



194 **Supplementary Figure 3. Global division by socio-demographic conditions.** EUR:
 195 Europe; EEUR: Eastern Europe; NAM: North America; CAM: Central America; SAM: South
 196 America; NAF: North Africa; WAF: West Africa; SAF: Southern Africa; EAF: East Africa;
 197 CAF: Central Africa; WAS: West Asia; CAS: Central Asia; SAS: South Asia, EAS: East Asia;
 198 SEA: South-East Asia.

199

200

201

202

203

204

205

206 **References**

207 1. Thorell K, Muñoz-Ramírez ZY, Wang D, Sandoval-Motta S, Boscolo Agostini R, Ghirotto
208 S, et al. The *Helicobacter pylori* Genome Project: insights into *H. pylori* population
209 structure from analysis of a worldwide collection of complete genomes. *Nat Commun.*
210 2023 Dec 11;14(1):8184.

211 2. Katoh K, Misawa K, Kuma K ichi, Miyata T. MAFFT: a novel method for rapid multiple
212 sequence alignment based on fast Fourier transform. *Nucleic Acids Res.* 2002 Jul
213 15;30(14):3059–66.

214 3. Page AJ, Taylor B, Delaney AJ, Soares J, Seemann T, Keane JA, et al. SNP-sites: rapid
215 efficient extraction of SNPs from multi-FASTA alignments. *Microb Genomics.* 2016
216 Apr;2(4):e000056.

217 4. Chen S. Ultrafast one-pass FASTQ data preprocessing, quality control, and
218 deduplication using fastp. *iMeta.* 2023 May;2(2):e107.

219 5. Li H. Aligning sequence reads, clone sequences and assembly contigs with BWA-MEM
220 [Internet]. *arXiv*; 2013 [cited 2024 Oct 29]. Available from: <http://arxiv.org/abs/1303.3997>

221 6. Danecek P, Bonfield JK, Liddle J, Marshall J, Ohan V, Pollard MO, et al. Twelve years of
222 SAMtools and BCFtools. *GigaScience.* 2021 Jan 29;10(2):giab008.

223 7. Koboldt DC, Chen K, Wylie T, Larson DE, McLellan MD, Mardis ER, et al. VarScan:
224 variant detection in massively parallel sequencing of individual and pooled samples.
225 *Bioinforma Oxf Engl.* 2009 Sep 1;25(17):2283–5.

226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252

254 ***HpGP Research Network***

255

256 Tuberculosis Genomics Unit, Instituto de Biomedicina de Valencia (IBV), CSIC

257 Francisco José Martínez-Martínez, Victoria Furió, & Iñaki Comas

258

259 Genomics of (Re)Emerging Pathogens, Genomics and Health Area, FISABIO – Public260 Health, Valencia, Spain

261 Álvaro Chiner-Oms

262

263 CIBER de Epidemiología y Salud Pública, CIBERESP, Madrid, Spain

264 Álvaro Chiner-Oms & Iñaki Comas

265

266 Department of Environmental and Preventive Medicine, Oita University Faculty of Medicine,267 Oita, Japan

268 Yoshio Yamaoka & Fabien Mbaya Tshibangu

269

270 Research Center for Global and Local Infectious Diseases, Oita University. Oita, Japan

271 Yoshio Yamaoka

272

273 Department of Medicine, Gastroenterology and Hepatology Section, Baylor College of274 Medicine, Houston, TX, USA

275 Yoshio Yamaoka

276

277 Bacterial Pathogenesis and Antimicrobial Resistance Section, Laboratory of Clinical278 Immunology and Microbiology, Division of Intramural Research, National Institute of Allergy279 and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA

280 John P. Dekker

281

282 INSERM, UMR1312 Bordeaux Institute of Oncology, University of Bordeaux, Bordeaux,283 France

284 Francis Megraud, Marine Jauvain, Christine Varon, & Philippe Lehours

285

286 National Reference Center for Campylobacters & Helicobacters, Bordeaux Hospital287 University Center, Bordeaux, France

288 Quentin Jehanne, Lucie Bénéjat, Astrid Ducournau, Marine Jauvain, & Philippe Lehours

289

290 Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA
291 Judith Romero-Gallo, Uma Krishna, Richard M. Peek Jr, M. Blanca Piazuelo, Keith T.
292 Wilson, John T. Loh & Timothy L. Cover
293
294 Veterans Affairs Tennessee Valley Healthcare System, Nashville, TN, USA
295 Timothy L. Cover & Keith T. Wilson
296
297 Instituto de Biosistemas e Ciências Integrativas, Faculdade de Ciências, Universidade de
298 Lisboa, Lisboa, Portugal
299 Filipa F. Vale
300
301 Department of Natural and Life Sciences, Faculty of Sciences, University of Algiers 1
302 Benyoucef Benkhedda, Algiers, Algeria
303 Naïma Raaf
304
305 Department of Gastroenterology, Dhaka Medical College and Hospital, Dhaka, Bangladesh
306 Hafeza Aftab
307
308 Department of Environmental and Preventive Medicine, Oita University Faculty of Medicine,
309 Yufu, Japan
310 Junko Akada, & Takashi Matsumoto
311
312 Department of Pathobiology, Pharmacology and Zoological Medicine, Faculty of Veterinary
313 Medicine, Ghent University, Ghent, Belgium
314 Freddy Haesebrouck
315
316 A.C.Camargo Cancer Center, São Paulo, São Paulo, Brazil
317 Thais F. Bartelli, Diana Noronha Nunes, Adriane Pelosof, Claudia Zitron Sztokfisz &
318 Emmanuel Dias-Neto
319
320 Division of Cancer Biology, Department of Radiation Oncology, Rutgers New Jersey Medical
321 School, Newark, NJ, USA
322 Diana Noronha Nunes & Emmanuel Dias-Neto
323
324 Núcleo de Pesquisas em Oncologia, Universidade Federal do Pará, Belém, Pará, Brazil
325 Paulo Pimentel Assumpção
326
327 Medical University of Sofia, Sofia, Bulgaria
328 Petko Karagyozev & Ivan Tishkov

329 Department of Medicine, University of Alberta, Edmonton, AB, Canada
330 Karen J. Goodman, Janis Geary, Taylor J. Cromarty & Nancy L. Price
331
332 Queen's University, Kingston, ON, Canada
333 Douglas Quilty
334
335 Department of Hematology and Oncology, Faculty of Medicine, Pontificia Universidad
336 Católica de Chile, Santiago, Chile
337 Alejandro H. Corvalan
338
339 Department of Gastroenterology, Faculty of Medicine, Pontificia Universidad Católica de
340 Chile, Instituto de Medicina. Red Salud UC Christus, Santiago, Chile
341 Robinson Gonzalez & Arnoldo Riquelme
342
343 Centro para la Prevención y Control del Cáncer (CECAN), Santiago, Chile
344 Arnoldo Riquelme
345
346 Facultad de Ciencias Biológicas, Universidad de Concepción, Concepción, Chile
347 Apolinaria García-Cancino & Cristian Parra-Sepúlveda
348
349 Doctorado en Ciencias mención Biología Celular y Molecular Aplicada, Universidad de la
350 Frontera, Temuco, Chile
351 Cristian Parra-Sepúlveda
352
353 Hospital Hanga Roa, Easter Island, Chile
354 Francisco Castillo
355
356 Grupo de Investigación en Biología del Cáncer, Instituto Nacional de Cancerología, Bogotá
357 DC, Colombia
358 Maria Mercedes Bravo
359
360 Departamento de Biología, Universidad de Nariño, Pasto, Nariño, Colombia
361 Alvaro Pazos
362
363 Escuela de Medicina, Universidad del Valle, Cali, Valle, Colombia
364 Luis E. Bravo
365
366 Division of Comparative Medicine, Department of Biological Engineering, Massachusetts
367 Institute of Technology, Cambridge, MA, USA

368 James G. Fox
369
370 Instituto de Investigaciones en Salud, Universidad de Costa Rica, San Jose, Costa Rica
371 Vanessa Ramírez-Mayorga & Silvia Molina-Castro
372
373 Laboratorio de Patología General y Gastrointestinal (LABGIPAT), San Jose, Costa Rica
374 Sundry Durán-Bermúdez
375
376 Servicio de Gastroenterología y Endoscopía Digestiva, Hospital Clínica Bíblica, San Jose,
377 Costa Rica
378 Christian Campos-Núñez & Manuel Chaves-Cervantes
379
380 Faculty of Medicine, Osaka Metropolitan University, Osaka, Japan
381 Evariste Tshibangu-Kabamba
382
383 Faculty of Medicine, University of Mbuji-Mayi, Mbuji Mayi, Kasai-Oriental, Democratic
384 Republic of the Congo
385 Evariste Tshibangu-Kabamba, Ghislain Disashi Tumba, Fabien Mbaya Tshibangu & Alain
386 Cimuanga Mukanya
387
388 Faculty of Medicine, University of Kinshasa, Kinshasa, Democratic Republic of the Congo
389 Antoine Tshimpi-Wola & Patrick de Jesus Ngoma-Kisoko
390
391 Instituto de Microbiología y Parasitología, Universidad Autónoma de Santo Domingo, Santo
392 Domingo, Dominican Republic
393 Modesto Cruz
394
395 Dominican-Japanese Digestive Disease Center, Dr Luis E. Aybar Health and Hygiene City,
396 Santo Domingo, Dominican Republic
397 José Jiménez Abreu
398
399 Medical Research Council Unit, The Gambia at the London School of Hygiene & Tropical
400 Medicine, Banjul, The Gambia
401 Ousman Secka
402
403 Department of Gastroenterology, Hepatology and Infectious Diseases, Otto-von-Guericke
404 University Magdeburg, Magdeburg, Germany
405 Peter Malfertheiner
406
16

407 Department of Gastroenterology, Friedrich-Alexander University, Erlangen-Nuremberg
408 (FAU), Medical Campus Upper Franconia, Klinikum Bayreuth GmbH, Bayreuth, Germany
409 Alexander Link
410
411 Department of Biochemistry, School of Biological Sciences, University of Cape Coast, Cape
412 Coast, Central Region, Ghana
413 Michael Buenor Adinortey
414
415 Department of Internal Medicine and Therapeutics, School of Medical Sciences, University
416 of Cape Coast, Cape Coast, Central Region, Ghana
417 Ansumana Sandy Bockarie
418
419 Department of Molecular Biology and Biotechnology, School of Biological Sciences,
420 University of Cape Coast, Cape Coast, Central Region, Ghana
421 Cynthia Ayefoumi Adinortey
422
423 Department of Biology Education, Faculty of Science Education, University of Education,
424 Winneba, Ghana
425 Eric Gyamerah Ofori
426
427 Laboratory of Medical Microbiology, Hellenic Pasteur Institute, Athens, Greece
428 Dionyssios N. Sgouras & Beatriz Martinez-Gonzalez
429
430 Department of Gastroenterology, Alexandra Hospital, Athens, Greece
431 Spyridon Michopoulos
432
433 Department of Gastroenterology, Athens Medical, P. Faliron Hospital, Athens, Greece
434 Sotirios Georgopoulos
435
436 Facultad de Ciencias Médicas, University of San Carlos of Guatemala, Guatemala City,
437 Guatemala
438 Elisa Hernandez
439
440 Departamento de Medicina Interna, Hospital de Occidente, Santa Rosa de Copán, Honduras
441 Ricardo L. Dominguez
442
443 School of Medicine, University of Alabama at Birmingham (UAB), Birmingham, AL, USA
444 Douglas R. Morgan
445
17

446 Landspítali – The National University Hospital of Iceland, Reykjavík, Iceland
447 Hjördís Harðardóttir, Anna Ingibjörg Gunnarsdóttir, Hallgrímur Guðjónsson, Jón Gunnlaugur
448 Jónasson & Einar S. Björnsson
449
450 University of Iceland, Reykjavík, Iceland
451 Jón Gunnlaugur Jónasson & Einar S. Björnsson
452
453 Department of Microbiology, Kasturba Medical College, Manipal Academy of Higher
454 Education, Manipal, Karnataka, India
455 Mamatha Ballal & Vignesh Shetty
456
457 Department of Medicine, University of Cambridge, Cambridge, UK
458 Vignesh Shetty
459
460 Universitas Airlangga, Surabaya, East Java, Indonesia
461 Muhammad Miftahussurur, Titong Sugihartono, Ricky Indra Alfaray, & Langgeng Agung
462 Waskito
463
464 National Research and Innovation Agency, Jakarta, Indonesia
465 Kartika Afrida Fauzia
466
467 Division of Gastroenterology, Department of Internal Medicine, Faculty of Medicine,
468 Universitas Indonesia/Cipto Mangunkusumo Hospital, Jakarta, Indonesia
469 Ari Fahrial Syam & Hasan Maulahela
470
471 Digestive Disease Research Institute, Tehran University of Medical Sciences, Tehran, Iran
472 Reza Malekzadeh
473
474 Clinical Microbiology Laboratory and Research Institute, Tzafon Medical Center, affiliated
475 with Azrieli Faculty of Medicine, Bar Ilan University, Poriya, Israel
476 Avi Peretz & Maya Azrad
477
478 Azrieli Faculty of Medicine, Bar Ilan University, Safed, Israel
479 Avi Peretz, Maya Azrad & Avi On
480
481 Pediatric Gastroenterology and Nutrition Unit, Tzafon Medical Center, Poriya, Israel
482 Avi On
483
484 Unit of Immunopathology and Oncological Biomarkers, Centro di Riferimento Oncologico di

485 Aviano (CRO) IRCCS, Aviano, Italy
486 Valli De Re & Stefania Zanussi
487
488 Unit of Oncological Gastroenterology, Centro di Riferimento Oncologico di Aviano (CRO),
489 IRCCS, Aviano, Italy
490 Renato Cannizzaro
491
492 Unit of Pathology, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, Aviano, Italy
493 Vincenzo Canzonieri
494
495 Department of Medical, Surgical and Health Sciences, University of Trieste, Italy
496 Renato Cannizzaro & Vincenzo Canzonieri
497
498 Department of Gastroenterology and Metabolism, Nagoya City University Graduate School
499 of Medical Sciences, Nagoya, Japan
500 Takaya Shimura
501
502 School of Medicine, Kyorin University, Mitaka, Tokyo, Japan
503 Kengo Tokunaga, Takako Osaki & Shigeru Kamiya
504
505 Faculty of Medicine, Jordan University of Science and Technology, Ar Ramtha-Irbid, Jordan
506 Khaled Jadallah & Ismail Matalka
507
508 Research Institute of Life and Health Sciences, Higher School of Medicine, Kokshetau
509 University named after Sh. Ualikhanov, Kokshetau, Kazakhstan
510 Nurbek Sagynbekuly Igissin
511
512 Central Asian Institute for Medical Research, Astana, Kazakhstan
513 Nurbek Sagynbekuly Igissin
514
515 Asian Pacific Organization for Cancer Prevention, Bishkek, Kyrgyzstan
516 Nurbek Sagynbekuly Igissin
517
518 Kyrgyz State Medical Academy, Bishkek, Kyrgyzstan
519 Mariia Satarovna Moldobaeva & Attokurova Rakhat
520
521 Center for Gastric Cancer, National Cancer Center, Goyang, South Korea
522 Il Ju Choi
523
19

524 Department of Internal Medicine, Chung-Ang University Hospital, Seoul, South Korea
525 Jae Gyu Kim
526
527 College of Medicine, Seoul National University, Seoul, South Korea
528 Nayoung Kim
529
530 Institute of Clinical and Preventive Medicine, University of Latvia, Riga, Latvia
531 Mārcis Leja, Reinis Vangravs, Ģirts Šķenders, Aiga Rūdule & Ilze Kikuste
532
533 Digestive Diseases Centre GASTRO, Riga, Latvia
534 Mārcis Leja & Aigars Vanags
535
536 Riga East University Hospital, Riga, Latvia
537 Mārcis Leja, Ģirts Šķenders & Dace Rudzīte
538
539 Department of Gastroenterology and Institute for Digestive Research, Lithuanian University
540 of Health Sciences, Kaunas, Lithuania
541 Juozas Kupcinskis, Edita Kiudeliene, Vytautas Kiudelis Rolandas Gedgaudas, Paulius
542 Jonaitis, Gediminas Kiudelis, Laimas Jonaitis, & Jurgita Skieceviciene
543
544 Department of Medical Microbiology, Faculty of Medicine, Universiti Malaya, Kuala Lumpur,
545 Malaysia
546 Jamuna Vadivelu, Mun Fai Loke & Kumutha Malar Vellasamy
547
548 Medical Education, Research and Development Unit, Faculty of Medicine, Universiti Malaya,
549 Kuala Lumpur, Malaysia
550 Jamuna Vadivelu
551
552 Departamento de Patología, Instituto Nacional de Cancerología, Mexico City, Mexico
553 Roberto Herrera-Goepfert
554
555 Servicio de Endoscopia, Instituto Nacional de Cancerología, Mexico City, Mexico
556 Juan Octavio Alonso-Larraga
557
558 Department of Gastrointestinal and Hepatobiliary Surgery, Defence Services General
559 Hospital (2/1000), Nay Pyi Taw, Myanmar
560 Than Than Yee
561
562 Department of Surgery, Defence Services General Hospital (1/1000), Yangon, Yangon

563 Region, Myanmar
564 Kyaw Htet
565
566 Department of Gastroenterology, St. Marianna University School of Medicine, Kawasaki,
567 Kanagawa Japan
568 Takeshi Matsuhisa
569
570 Department of Gastroenterology, Maharaigunj Medical Campus, Tribhuvan University
571 Teaching Hospital, Kathmandu, Nepal
572 Pradeep Krishna Shrestha
573
574 Division of Health Sciences, Abu Dhabi Women's Campus, Higher Colleges of Technology,
575 Abu Dhabi, United Arab Emirates
576 Shamshul Ansari
577
578 Department of Community Medicine, Babcock University, Ilishan, Ogun State, Nigeria
579 Olumide Abiodun
580
581 Department of Medicine, Babcock University, Ilishan, Ogun State, Nigeria
582 Christopher Jemilohun
583
584 Department of Medicine, College of Medicine, University of Ibadan, Ibadan, Oyo, Nigeria
585 Kolawole Oluseyi Akande
586
587 Department of Nursing, Crescent University, Abeokuta, Ogun State, Nigeria
588 Oluwatosin Olu-Abiodun
589
590 University Teaching Hospital, University of Jos, Jos, Plateau, Nigeria
591 Francis Ajang Magaji
592
593 University of Calabar Teaching Hospital, Calabar, Cross River, Nigeria
594 Ayodele Omotoso & Uchenna Okonkwo
595
596 University of Nigeria Teaching Hospital, Ituku-Ozalla, Enugu State, Nigeria
597 Chukwuemeka Chukwunwendu Osuagwu
598
599 Department of Internal Medicine, Federal Medical Center Abeokuta, Abeokuta, Ogun State,
600 Nigeria
601 Opeyemi O. Owoseni

602
603 Faculty of Health Sciences, Universidad Científica del Sur, Lima, Peru
604 Carlos Castaneda
605
606 Departamento de investigación, Instituto Nacional de Enfermedades Neoplásicas, Lima,
607 Peru
608 Miluska Castillo
609
610 Universidad Peruana Cayetano Heredia, Lima, Peru
611 Billie Velapatino
612
613 Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD, USA
614 Robert H. Gilman
615
616 Department of Microbiology, Wrocław Medical University, Wrocław, Poland
617 Paweł Krzyżek & Grażyna Gościńskiak
618
619 Department of Surgery Teaching, Wrocław Medical University, Wrocław, Poland
620 Dorota Pawełka
621
622 Department of Pharmaceutical Microbiology, Medical University of Lublin, Lublin, Poland
623 Izabela Korona-Główniak
624
625 Department of Gastroenterology with Endoscopic Unit, Medical University of Lublin, Lublin,
626 Poland
627 Halina Cichoż-Lach
628
629 Instituto Nacional de Saúde Dr. Ricardo Jorge, Lisboa, Portugal
630 Mónica Oleastro
631
632 Instituto de Patologia e Imunologia Molecular da Universidade do Porto, Porto, Portugal
633 Ceu Figueiredo, Jose C. Machado & Rui M. Ferreira
634
635 Instituto de Investigação e Inovação em Saúde, Universidade do Porto, Porto, Portugal
636 Ceu Figueiredo, Jose C. Machado & Rui M. Ferreira
637
638 Faculdade de Medicina da Universidade do Porto, Porto, Portugal
639 Ceu Figueiredo & Jose C. Machado
640
22

641 Department of Pancreatic, Biliary and Upper Digestive Tract Disorders, A. S. Loginov
642 Moscow Clinical Scientific Center, Moscow, Russia
643 Dmitry S. Bordin
644
645 Department of General Medical Practice and Family Medicine, Tver State Medical
646 University, Moscow, Russia
647 Dmitry S. Bordin
648
649 Department of Propaedeutic of Internal diseases and Gastroenterology Russian University of
650 Medicine, Moscow, Russia
651 Dmitry S. Bordin
652
653 Department of Faculty Therapy and Gastroenterology, Omsk State Medical University,
654 Omsk, Russia
655 Maria A. Livzan
656
657 Scientific Research Institute of Medical Problems of the North, Federal Research Centre
658 “Krasnoyarsk Science Centre” of the Siberian Branch of Russian Academy of Science,
659 Krasnoyarsk, Russia
660 Vladislav V. Tsukanov
661
662 Cancer Science Institute of Singapore, National University of Singapore, Singapore,
663 Singapore
664 Patrick Tan
665
666 Cancer and Stem Cell Biology Program, Duke NUS Medical School, Singapore, Singapore
667 Patrick Tan
668
669 Genome Institute of Singapore, Agency for Science, Technology and Research, Singapore,
670 Singapore
671 Patrick Tan
672
673 Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore,
674 Singapore, Singapore
675 Khay Guan Yeoh & Feng Zhu
676
677 Department of Gastroenterology and Hepatology, National University Health System,
678 Singapore, Singapore
679 Khay Guan Yeoh

680
681 Chris Hani Baragwanath Academic Hospital, Johannesburg, South Africa
682 Reid Ally
683
684 University of the Witwatersrand, Johannesburg, South Africa
685 Reid Ally
686
687 Max von Pettenkofer Institute of Hygiene and Medical Microbiology, Faculty of Medicine,
688 LMU Munich, Munich, Germany
689 Rainer Haas & Wolfgang Fischer
690
691 Hospital Universitario Donostia, San Sebastian, Spain
692 María Fernández-Reyes, Esther Tamayo & Jacobo Lizasoain
693
694 Donostia University Hospital-BioGipuzkoa Health Research Institute, San Sebastian-
695 Donostia, Gipuzkoa, Spain
696 Milagrosa Montes
697
698 Department of Gastroenterology, BioDonostia Health Research Institute - Donostia
699 University Hospital, Universidad del País Vasco (UPV/EHU), Centro de Investigación
700 Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), San Sebastian,
701 Spain
702 Luis Bujanda
703
704 Digestive Diseases Unit, Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació
705 Parc Taulí (I3PT-CERCA), Universitat Autònoma de Barcelona, Barcelona, Spain
706 Sergio Lario, María José Ramírez-Lázaro, Xavier Calvet & Eduard Brunet-Mas
707
708 Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas,
709 Instituto de Salud Carlos III, Madrid, Spain
710 Sergio Lario, María José Ramírez-Lázaro, Xavier Calvet & Eduard Brunet-Mas
711
712 Barbastro General Hospital, Huesca, Spain
713 María José Domper-Arnal
714
715 Lozano Blesa University Clinic Hospital, Zaragoza, Spain
716 Sandra García-Mateo
717
718 Aragon Health Research Institute, Zaragoza, Spain

719 María José Domper-Arnal & Sandra García-Mateo
720
721 Miguel Servet University Hospital, Zaragoza, Spain
722 Daniel Abad-Baroja
723
724 Hospital General de Granollers, Barcelona, Spain
725 Pedro Delgado-Guillena
726
727 Gastroenterology Department, Hospital Clínic of Barcelona, Centro de Investigación
728 Biomédica en Red de Enfermedades Hepáticas y Digestivas, Facultat de Medicina i
729 Ciències de la Salut, Universitat de Barcelona, Barcelona, Spain
730 Leticia Moreira
731
732 Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain
733 Josep Botargues
734
735 Department of Gastroenterology, Hospital Universitario Central de Asturias, Oviedo,
736 Asturias, Spain
737 Isabel Pérez-Martínez & Eva Barreiro-Alonso
738
739 Diet, Microbiota and Health Group, Instituto de Investigación Sanitaria del Principado de
740 Asturias, Oviedo, Asturias, Spain
741 Isabel Pérez-Martínez
742
743 Farmacology Group, Instituto de Investigación Sanitaria del Principado de Asturias, Oviedo,
744 Asturias, Spain
745 Eva Barreiro-Alonso
746
747 Instituto Universitario de Oncología del Principado de Asturias, Oviedo, Asturias, Spain
748 Eva Barreiro-Alonso
749
750 Hospital General Universitario Gregorio Marañón, Madrid, Spain
751 Virginia Flores
752
753 Gastroenterology Unit, Hospital Universitario de La Princesa, Instituto de Investigación
754 Sanitaria Princesa, Madrid, Spain
755 Javier P. Gisbert
756
757 Universidad Autónoma de Madrid, Centro de Investigación Biomédica en Red de
25

758 Enfermedades Hepáticas y Digestivas, Madrid, Spain
759 Javier P. Gisbert
760
761 Gastroenterology Department, Hospital Universitario de Navarra, Pamplona, Navarra, Spain
762 Edurne Amorena Muro
763
764 Hospital de Leon, Leon, Spain
765 Pedro Linares & Laura Alcoba
766
767 Institut of Biomedicine, University of León, Consortium for Biomedical Research in
768 Epidemiology and Public Health, Leon, Spain
769 Vicente Martin
770
771 Centre for Translational Microbiome Research, Department of Microbiology, Tumor and Cell
772 Biology, Karolinska Institutet, Solna, Sweden
773 Lars Engstrand
774
775 University of Skövde, Skövde, Sweden
776 Helena Enroth
777
778 Institute for Infectious Diseases, University of Bern, Bern, Switzerland
779 Peter M. Keller
780
781 Clinical Bacteriology/Myology Unit, University Hospital Basel, Basel, Switzerland
782 Peter M. Keller
783
784 Clinical Virology, University Hospital Basel, Basel, Switzerland
785 Karoline Leuzinger
786
787 Clinic for Gastroenterology and Hepatology, University Hospital Zurich, Zürich, Switzerland
788 Daniel Pohl
789
790 College of Medicine, National Taiwan University, Taipei City, Taiwan
791 Yi-Chia Lee, Jyh-Ming Liou & Ming-Shiang Wu
792
793 Medical Microbiology Department, Cerrahpasa Medical Faculty, Istanbul University-
794 Cerrahpasa, İstanbul, Türkiye
795 Bekir Kocazeybek & Suat Saribas
796
26

797 General Surgery Department, Cerrahpasa Medical Faculty, Istanbul University-Cerrahpasa,
798 İstanbul, Türkiye
799 İhsan Tasci & Süleyman Demiryas
800
801 Medical Pathology Department, Cerrahpasa Medical Faculty, Istanbul University-
802 Cerrahpasa, İstanbul, Türkiye
803 Nuray Kepil
804
805 Northwell Staten Island University Hospital, New York City, NY, USA
806 Luis Quiel
807
808 Carson Tahoe Regional Medical Center, Carson City, NV, USA
809 Miguel Villagra
810
811 White River Medical Center, Batesville, AR, USA
812 Morgan Norton & Deborah Johnson
813
814 Department of Medicine, Stanford University, Stanford, CA, USA
815 Robert J. Huang & Joo Ha Hwang
816
817 Albert Einstein College of Medicine, Bronx, NY, USA
818 Wendy Szymczak, William R. Jacobs Jr. & Haejin In
819
820 Rutgers Cancer Institute, New Brunswick, NJ, USA
821 Haejin In, Diana Noronha Nunes & Emmanuel Dias-Neto
822
823 Georgia Cancer Center's Biorepository, Augusta University, Augusta, GA, USA
824 Roni Bollag & Aileen Lopez
825
826 Augusta University Medical Center, Augusta, GA, USA
827 Edward J. Kruse & Joseph White
828
829 Enteric Diseases Laboratory Branch, Division of Foodborne, Waterborne, and Environmental
830 Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA
831 Charlotte Lane & Yang Gao
832
833 Gi Care for Kids, LLC, Children's Center for Digestive Healthcare, LLC, Atlanta, GA, USA
834 Benjamin D. Gold
835
27

836 University of Puerto Rico Comprehensive Cancer Center, San Juan, Puerto Rico
837 Marcia Cruz-Correa & María González-Pons
838
839 University of Puerto Rico Medical Sciences Campus, San Juan, Puerto Rico
840 Marcia Cruz-Correa
841
842 Gastrointestinal and Other Cancers Research Group, Division of Cancer Prevention,
843 National Cancer Institute, Rockville, MD, USA
844 Luz M. Rodriguez
845
846 Department of Endoscopy, Cho Ray Hospital, Ho Chi Minh City, Vietnam
847 Vo Phuoc Tuan & Ho Dang Quy Dung
848
849 GI Endoscopy Center, Tam Anh Hospital, Ho Chi Minh City, Vietnam
850 Tran Thanh Binh
851
852 Center for Stem Cell Research and Applications, 108 Military Central Hospital, Hanoi,
853 Vietnam
854 Tran Thi Huyen Trang
855
856 GI Endoscopy Center, Thu Cuc International Hospital, Hanoi, Vietnam
857 Vu Van Kien
858
859 Center for the Evolutionary Origins of Human Behavior, Kyoto University, Inuyama, Japan
860 Yukako Katsura
861
862 Instituto de Ciencias Biomédicas (ICBM), Facultad de Medicina, Universidad de Chile,
863 Santiago, Chile
864 Patricio Gonzalez-Hormazabal
865
866 Departamento de Genética, Ecologia e Evolução, Universidade Federal de Minas Gerais,
867 Belo Horizonte, Brazil
868 Eduardo Tarazona-Santos & Roxana Zamudio
869
870 National Institute on Minority Health and Health Disparities, Bethesda, MD, USA
871 Leonardo Mariño-Ramírez
872
873 Division of Microbiology, Department of Biology, Friedrich-Alexander-Universität Erlangen-
874 Nürnberg, Erlangen, Germany

875 Steffen Backert
876
877 Institute of Experimental Internal Medicine, Otto-von-Guericke-Universität Magdeburg,
878 Magdeburg, Germany
879 Michael Naumann
880
881 Laboratory of Experimental Medicine and Pediatrics, Faculty of Medicine and Health
882 Sciences, University of Antwerp, Antwerp, Belgium
883 Annemieke Smet
884
885 Department of Molecular Microbiology, Washington University School of Medicine, St. Louis,
886 MO, USA
887 Douglas E. Berg
888
889 Quadram Institute Bioscience, Norwich, UK
890 Roxana Zamudio
891
892 National Institute of Infectious Diseases, Tokyo, Japan
893 Koji Yahara
894
895 Center for Advanced Biotechnology and Medicine, Rutgers University, New Brunswick, NJ,
896 USA
897 Martin J. Blaser
898
899 New England Biolabs, Ipswich, MA, USA
900 Tamas Vincze, Richard D. Morgan & Richard J. Roberts
901
902 Unidad de Investigación en Enfermedades Infecciosas y Parasitarias, UMAE Pediatría,
903 Instituto de Seguro Social, Mexico City, Mexico
904 Javier Torres & Roberto C. Torres
905
906 Department of Genetics, SOKENDAI University, Mishima, Shizuoka, Japan
907 Mehwish Noureen
908
909 Computational Biology Branch, Division of Intramural Research, National Library of
910 Medicine, National Institutes of Health, Bethesda, MD, USA
911 Joshua L. Cherry
912
913 Faculty of Information Science and Technology, Hokkaido University, Sapporo, Japan

914 Naoki Osada
915
916 Department of Molecular Oncology, Chiba University, Chiba, Japan
917 Masaki Fukuyo
918
919 Bioinformation and DDBJ Center, National Institute of Genetics, Mishima, Shizuoka, Japan
920 Masanori Arita
921
922 Instituto Nacional de Medicina Genómica, Ciudad de México, México
923 Santiago Sandoval-Motta
924
925 Consejo Nacional de Ciencia y Tecnología, Cátedras CONACYT, Ciudad de México, México
926 Santiago Sandoval-Motta
927
928 Centro de Ciencias de la Complejidad, Universidad Nacional Autónoma de México, Ciudad
929 de México, México
930 Santiago Sandoval-Motta
931
932 Department of Life Sciences and Biotechnology, University of Ferrara, Ferrara, Italy
933 Rajiv Boscolo Agostini & Silvia Ghirotto
934
935 Facultad de Ciencias Químicas, Universidad Autónoma de Chihuahua, Chihuahua,
936 Chihuahua, México
937 Zilia Y. Muñoz-Ramírez
938
939 Centre for Microbes Development and Health, Institute Pasteur Shanghai, Shanghai, China
940 Daniel Falush
941
942 Department of Chemistry and Molecular Biology, University of Gothenburg, Gothenburg,
943 Sweden
944 Kaisa Thorell
945
946 National Institute for Basic Biology, National Institutes of Natural Sciences, Aichi, Japan
947 Ikuo Uchiyama, Ichizo Kobayashi
948
949 Research Center for Micro-Nano Technology, Hosei University, Tokyo, Japan
950 Ichizo Kobayashi
951
952 Laboratory of Epidemiology and Population Sciences, National Institute on Aging, Baltimore,

953 MD, USA
954 Minkyong Song
955
956 Cancer Genomics Research Laboratory, Frederick National Laboratory for Cancer
957 Research, Frederick, MD, USA
958 Difei Wang, Belynda Hicks, Meredith Yeager, Amy Hutchinson, Kedest Teshome, Kristie
959 Jones & Wen Luo
960
961 Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD,
962 USA
963 Difei Wang, Alisa M. Goldstein, Nan Hu, Philip R. Taylor, Kai Yu, Bin Zhu, Christian C.
964 Abnet, Charles S. Rabkin, & M. Constanza Camargo